DK2934584T3 - Anti-gdf15-antistoffer - Google Patents
Anti-gdf15-antistoffer Download PDFInfo
- Publication number
- DK2934584T3 DK2934584T3 DK13827058.2T DK13827058T DK2934584T3 DK 2934584 T3 DK2934584 T3 DK 2934584T3 DK 13827058 T DK13827058 T DK 13827058T DK 2934584 T3 DK2934584 T3 DK 2934584T3
- Authority
- DK
- Denmark
- Prior art keywords
- gdf15 antibodies
- gdf15
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745508P | 2012-12-21 | 2012-12-21 | |
| US201361827325P | 2013-05-24 | 2013-05-24 | |
| PCT/US2013/077139 WO2014100689A1 (en) | 2012-12-21 | 2013-12-20 | Anti-gdf15 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2934584T3 true DK2934584T3 (da) | 2020-05-18 |
Family
ID=50069279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13827058.2T DK2934584T3 (da) | 2012-12-21 | 2013-12-20 | Anti-gdf15-antistoffer |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9175076B2 (da) |
| EP (2) | EP3689370B1 (da) |
| JP (3) | JP6758832B2 (da) |
| KR (1) | KR102208861B1 (da) |
| CN (1) | CN105073133B (da) |
| AR (1) | AR094271A1 (da) |
| AU (1) | AU2013364133B2 (da) |
| CA (1) | CA2896076C (da) |
| DK (1) | DK2934584T3 (da) |
| EA (1) | EA038645B1 (da) |
| ES (1) | ES2791183T3 (da) |
| MX (1) | MX370720B (da) |
| WO (1) | WO2014100689A1 (da) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| WO2013113008A1 (en) | 2012-01-26 | 2013-08-01 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
| US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| SG11201500873XA (en) | 2012-08-24 | 2015-04-29 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc region variant |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| PT2900263T (pt) | 2012-09-26 | 2019-07-29 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15) |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
| UA116665C2 (uk) | 2013-07-31 | 2018-04-25 | Емджен Інк. | Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15) |
| EP3063543B1 (en) * | 2013-10-31 | 2020-03-11 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| EP4417255A3 (en) | 2013-11-21 | 2024-10-23 | The Brigham and Women's Hospital Inc. | Compositions and methods for treating pulmonary hypertension |
| MX2016012124A (es) | 2014-03-19 | 2017-04-06 | Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. |
| EP3122775B1 (en) * | 2014-03-26 | 2019-11-13 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| GB2524553C (en) * | 2014-03-26 | 2017-07-19 | Julius-Maximilians-Universitãt Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| GB2524552B (en) * | 2014-03-26 | 2017-07-12 | Julius-Maximilians-Universitãt Wurzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| MX2016016826A (es) | 2014-06-20 | 2017-08-28 | Aveo Pharmaceuticals Inc | Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15. |
| WO2015196142A1 (en) * | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| TN2016000578A1 (en) | 2014-07-30 | 2018-04-04 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| JP6955443B2 (ja) * | 2014-08-01 | 2021-10-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 肺動脈性肺高血圧症の処置に関する方法および組成物 |
| HUE054670T2 (hu) * | 2014-09-25 | 2021-09-28 | Aveo Pharmaceuticals Inc | Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával |
| US20170290885A1 (en) * | 2014-09-30 | 2017-10-12 | Universiteit Gent | A method of treating joint disease |
| CA2964808C (en) | 2014-10-30 | 2023-06-27 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| EP3212226B1 (en) | 2014-10-31 | 2020-03-18 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| RU2743188C2 (ru) | 2015-04-23 | 2021-02-16 | Хемалоджикс Пти. Лтд. | Химерные антигенные рецепторы к каппа-антигену миеломы и варианты их применения |
| CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
| GB201512733D0 (en) * | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| JP6858181B2 (ja) | 2015-10-02 | 2021-04-14 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ |
| JP6925326B2 (ja) | 2015-10-02 | 2021-08-25 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 |
| CN108463247B (zh) * | 2015-10-28 | 2022-04-12 | 耶鲁大学 | 人源化的抗dkk2抗体和其用途 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3411066B1 (en) * | 2016-02-01 | 2026-05-13 | Eli Lilly and Company | Parathyroid hormone anti-rankl antibody fusion compounds |
| JP2019510739A (ja) * | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Ｇｆｒａｌ受容体療法 |
| AU2017228489A1 (en) * | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CN109071647B (zh) * | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | 抗生长分化因子15的抗体及其用途 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| EA201990296A1 (ru) * | 2016-08-05 | 2019-08-30 | Аллакос, Инк. | Антитела против siglec-7 для лечения рака |
| CA3045700A1 (en) * | 2016-12-06 | 2018-06-14 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| JP7280238B2 (ja) * | 2017-07-17 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 |
| AU2019208025A1 (en) * | 2018-01-11 | 2020-09-03 | Allakos, Inc. | Anti-Siglec-7 antibodies having reduced effector function |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| PE20201350A1 (es) | 2018-04-09 | 2020-11-30 | Amgen Inc | Proteinas de fusion del factor de diferenciacion de crecimiento 15 |
| US12595293B2 (en) | 2018-08-09 | 2026-04-07 | The Wistar Institute | Anti-follicle stimulating hormone receptor antibodies |
| CA3109905A1 (en) | 2018-08-20 | 2020-02-27 | Pfizer Inc. | Anti-gdf15 antibodies, compositions and methods of use |
| KR102238927B1 (ko) * | 2018-08-30 | 2021-04-12 | 서울대학교산학협력단 | 세포 내에서 nag-1 단백질의 이동을 조절하는 펩티드 및 이의 용도 |
| WO2020053147A1 (en) * | 2018-09-10 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
| AU2019368816B2 (en) | 2018-10-22 | 2025-01-30 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof |
| US20220372125A1 (en) * | 2019-10-02 | 2022-11-24 | Aslan Pharmaceuticals Pte. Ltd. | Antigen Specific Binding Domains and Antibody Molecules |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| WO2021111636A1 (ja) * | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗ｇｄｆ１５抗体 |
| CN111393526B (zh) * | 2020-03-30 | 2022-04-12 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
| TWI894280B (zh) * | 2020-05-26 | 2025-08-21 | 南韓商愛思阿爾法數字醫療科技有限公司 | 用以治療癌症惡病質之系統、用以治療癌症惡病質之運算系統及其操作方法、以及非暫態電腦可讀取媒體 |
| WO2021246773A1 (ko) * | 2020-06-04 | 2021-12-09 | 재단법인대구경북과학기술원 | Gfral 길항 항체 및 이의 용도 |
| CA3199951A1 (en) * | 2020-10-30 | 2022-05-05 | Hideaki Hara | Gdf15 modulators for use in inhibiting ocular tissue fibrosis |
| IL302646A (en) | 2020-11-10 | 2023-07-01 | Catalym Gmbh | Anti-GDF15 antibody and dosage regimen for cancer treatment |
| AR125037A1 (es) * | 2021-03-08 | 2023-05-31 | Medimmune Llc | Anticuerpos dirigidos contra gdf-15 |
| EP4314071A1 (en) | 2021-03-31 | 2024-02-07 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| EP4384545A1 (en) | 2021-08-10 | 2024-06-19 | BYOMass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| WO2023079430A1 (en) | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| AU2022437929A1 (en) * | 2022-01-26 | 2024-08-08 | Yunnan Baiyao Group Co., Ltd. | Antibody molecule against growth and differentiation factor 15 and use thereof |
| CN119487065A (zh) | 2022-05-09 | 2025-02-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
| CN116041497A (zh) * | 2022-12-22 | 2023-05-02 | 杭州贤至生物科技有限公司 | 一种猫杯状病毒（fcv）重组蛋白单克隆抗体及制备方法 |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
| AU2024352029A1 (en) * | 2023-09-27 | 2026-04-09 | Aveo Pharmaceuticals, Inc. | Methods of reducing weight loss using anti-gdf15 antibodies |
| WO2025146488A1 (en) | 2024-01-05 | 2025-07-10 | Catalym Gmbh | Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| EP0833912B1 (en) | 1995-06-22 | 2009-02-25 | St Vincent's Hospital Sydney Limited | Novel tgf-beta like cytokine |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| AU1103900A (en) | 1998-10-07 | 2000-04-26 | Stryker Corporation | Modified tgf-beta superfamily proteins |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| ATE348164T1 (de) | 1999-05-17 | 2007-01-15 | Bioph Biotech Entw Pharm Gmbh | Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie |
| EP1914554B1 (en) | 2000-04-20 | 2010-06-09 | St Vincent's Hospital Sydney Limited | Diagnostic assay involving macrophage inhibitory cytokine-1 (MIC-1) |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| EP1578367A4 (en) | 2002-11-01 | 2012-05-02 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| US20040253207A1 (en) | 2002-11-08 | 2004-12-16 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US20060188889A1 (en) | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
| CN1890880B (zh) | 2003-10-10 | 2013-05-22 | 塔特公司 | 具有宽动态范围的低功率集成电路信号处理器 |
| US7981598B2 (en) | 2004-03-26 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Preventive/remedy for respiratory diseases |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| CA2534871C (en) | 2006-02-15 | 2015-08-04 | The Ohio State University Research Foundation | Three-gene test to differentiate malignant from benign thyroid nodules |
| US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
| EP1884777A1 (en) | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| WO2008015254A2 (en) | 2006-08-04 | 2008-02-07 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| EP2783698A1 (en) * | 2007-08-16 | 2014-10-01 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
| US20100266707A1 (en) | 2007-10-09 | 2010-10-21 | Samuel Norbert Breit | Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| EP2103943A1 (en) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs |
| JP2011523051A (ja) | 2008-05-20 | 2011-08-04 | エフ．ホフマン−ラ ロシュ アーゲー | １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５ |
| GB0902793D0 (en) * | 2009-02-20 | 2009-04-08 | Univ Gent | GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| GB201004739D0 (en) | 2010-03-22 | 2010-05-05 | Prosidion Ltd | Receptor modulators |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| WO2015196142A1 (en) | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| MX2016016826A (es) | 2014-06-20 | 2017-08-28 | Aveo Pharmaceuticals Inc | Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15. |
-
2013
- 2013-12-20 CA CA2896076A patent/CA2896076C/en active Active
- 2013-12-20 WO PCT/US2013/077139 patent/WO2014100689A1/en not_active Ceased
- 2013-12-20 EP EP20156883.9A patent/EP3689370B1/en active Active
- 2013-12-20 US US14/137,415 patent/US9175076B2/en active Active
- 2013-12-20 AU AU2013364133A patent/AU2013364133B2/en active Active
- 2013-12-20 AR ARP130105017A patent/AR094271A1/es active IP Right Grant
- 2013-12-20 EP EP13827058.2A patent/EP2934584B1/en active Active
- 2013-12-20 CN CN201380073317.1A patent/CN105073133B/zh active Active
- 2013-12-20 MX MX2015007751A patent/MX370720B/es active IP Right Grant
- 2013-12-20 ES ES13827058T patent/ES2791183T3/es active Active
- 2013-12-20 KR KR1020157019881A patent/KR102208861B1/ko active Active
- 2013-12-20 DK DK13827058.2T patent/DK2934584T3/da active
- 2013-12-20 EA EA201591198A patent/EA038645B1/ru unknown
- 2013-12-20 JP JP2015549810A patent/JP6758832B2/ja active Active
-
2015
- 2015-09-24 US US14/863,870 patent/US9725505B2/en active Active
-
2017
- 2017-07-20 US US15/655,263 patent/US10597444B2/en active Active
-
2019
- 2019-01-21 JP JP2019007928A patent/JP2019056018A/ja not_active Withdrawn
-
2020
- 2020-03-19 US US16/824,034 patent/US11725047B2/en active Active
-
2021
- 2021-01-25 JP JP2021009528A patent/JP2021061864A/ja not_active Withdrawn
-
2023
- 2023-06-16 US US18/336,713 patent/US12258391B2/en active Active
-
2025
- 2025-02-07 US US19/048,087 patent/US20250277019A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2024011I1 (el) | Αντισωματα anti-fcrn | |
| HUS2300021I1 (hu) | Anti-IL-36R antitestek | |
| EP3689370C0 (en) | ANTI-GDF15 ANTIBODY | |
| HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| EP2763896A4 (en) | UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS | |
| EP2930240A4 (en) | ANTI-FOLR1 ANTIBODY | |
| DK2859055T3 (da) | Polymercoatings | |
| DK2825087T3 (da) | Otoscanner | |
| BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| EP2847405A4 (en) | DOOR CLOSURE SYSTEM | |
| DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
| DE112012006109A5 (de) | Okklusionsschienenanordnung | |
| DK2854722T3 (da) | Stomipose | |
| ME03751B (me) | Antitela usmerena na beta-amiloid | |
| HRP20181874T1 (hr) | Anti-cxcr3 protutijela | |
| DK2825157T3 (da) | Aminosyrelipider | |
| DK3431504T3 (da) | Antiphospholipase d4-antistof | |
| DK3521315T3 (da) | Anti-transglutaminase-2-antistoffer | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
| DK2931748T3 (da) | Bmp-6-antistoffer | |
| DK2935330T3 (da) | Anti-notch3-antistoffer | |
| DE112012006214T8 (de) | Wulstringwickler | |
| DK2831122T3 (da) | Anthocyanidin-kompleks | |
| CO6841994A2 (es) | Anticuerpos |